A follow-up study to the ADMIRE-HF trial showed that cardiac imaging using iobenguane I-123 helps pinpoint heart-failure patients that have a low risk of fatal arrhythmic events and a higher-than-normal fatal and nonfatal arrhythmia risk. "We found that reduced myocardial sympathetic innervation on 123I-mIBG imaging is a strong and independent predictor of mortality in patients with advanced congestive heart failure," the study's lead investigator said.

Full Story:
Doctor's Guide

Related Summaries